西达本胺联合化疗治疗外周T细胞淋巴瘤的疗效研究  

Efficacy study of chidamide combined with chemotherapy in treatment of peripheral T cell lymphoma

作　　者：赖文普 郑润辉[1] 覃鹏飞[1] 王春燕[1] 黄振倩[1] 刘丹[1] 汪雅涯 李海明[1] 彭思达[1] 谭获[1] 罗晓丹[1] LAI Wen-pu;ZHENG Run-hui;QIN Peng-fei(Department of Hematology,First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510030,China)

机构地区：[1]广州医科大学附属第一医院血液科,510030

出　　处：《中国实用医药》2021年第19期25-27,共3页China Practical Medicine

摘　　要：目的探讨西达本胺联合化疗治疗外周T细胞淋巴瘤(PTCL)的临床疗效及安全性。方法31例初发PTCL患者,根据初始治疗方案不同分为实验组(16组)和参照组(15例)。参照组患者采用常规化疗治疗,实验组患者采用西达本胺联合化疗治疗。对比两组临床疗效、生存期及不良反应发生情况。结果实验组完全缓解率62.5%高于参照组的20.0%,差异有统计学意义(P<0.05);两组总有效率比较,差异无统计学意义(P>0.05)。实验组中位无进展生存期、总生存期分别为8.8、28.5个月,参照组中位无进展生存期、总生存期分别为4.7、6.3个月;实验组中位无进展生存期、总生存期均长于参照组,差异有统计学意义(P<0.05)。实验组1年无进展生存率、1年总生存率分别为50.0%(8/16)、68.8%(11/16),参照组1年无进展生存率、1年总生存率分别为13.3%(2/15)、26.7%(4/15);实验组无进展生存率、1年总生存率均高于参照组,差异有统计学意义(P<0.05)。实验组中性粒细胞减少、贫血、血小板减少、乏力、呕吐及心脏毒性发生率与参照组比较,差异均无统计学意义(P>0.05)。结论西达本胺联合化疗治疗PTCL能改善患者的生存情况,且安全性良好,可作为PTCL的一线治疗方案。Objective To discuss the clinical efficacy and safety of chidamide combined with chemotherapy in treatment of peripheral T cell lymphoma(PTCL).Methods A total of 31 patients with primary PTCL were divided into experimental group(16 cases)and reference group(15 cases)according to different initial treatment plan.The reference group was treated with conventional chemotherapy,and the experimental group was treated with chidamide combined with chemotherapy.The clinical efficacy,survival time and occurrence of adverse reactions of the two groups were compared.Results The complete remission rate 62.5%of the experimental group was higher than 20.0%of the reference group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in total effective rate between the two groups(P>0.05).The median progression-free survival and overall survival of the experimental group were 8.8 and 28.5 months,which were 4.7 and 6.3 months of the reference group.The median progression-free survival and overall survival of the experimental group were longer than those of the reference group,and the difference was statistically significant(P<0.05).The 1-year progression-free survival rate and 1-year overall survival rate of the experimental group were 50.0%(8/16)and 68.8%(11/16),which were 13.3%(2/15)and 26.7%(4/15)of the reference group.The 1-year progression-free survival rate and 1-year overall survival rate of the experimental group were higher than those of the reference group,and the difference was statistically significant(P<0.05).The incidence of neutropenia,anemia,thrombocytopenia,fatigue,vomiting and cardiotoxicity of the experimental group had no statistically significant difference compared with that of the reference group(P>0.05).Conclusion Combination of chidamide and chemotherapy can improve the survival time of PTCL patients with good safety,and it can be used as the first-line treatment of PTCL.

关 键 词：外周T细胞淋巴瘤 组蛋白去乙酰化酶抑制剂 西达本胺 化疗 

分 类 号：R733.1[医药卫生—肿瘤]